Discovery and Validation of an Epithelial-Mesenchymal Transition-Based Signature in Gastric Cancer by Genomics and Prognosis Analysis

Figure 7

Screening potential small molecular compounds and activated pathways associated with RS model in gastric cancer. (a) Candidate small molecular compounds that were predicted by the CMAP database based on differentially expressed EMT-related genes. -axis shows mechanism of action, and -axis represents small compounds. (b–d) Activated pathways in high-RS gastric cancer samples in (b) TCGA, (c) GSE66229, and (d) GSE84437 datasets.

(a)

(b)

(c)

(d)